Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis, NHS England Ink Access Deal For Cholesterol Drug Leqvio
06:23am, Wednesday, 01'st Sep 2021
The U.K. government, NHS England, and Novartis AG (NYSE: NVS) unveiled a "world-first" reimbursement deal for providing broader access to anti-cholesterol drug Leqvio (inclisiran) after the U.K.'s h
Novartis to provide cholesterol-lowering drug Leqvio to 300,000 U.K. patients
02:29am, Wednesday, 01'st Sep 2021
Novartis AG has reached a deal to provide its cholesterol-lowering medicine Leqvio to patients via the U.K.'s National Health Service, the Swiss pharmaceutical company said Wednesday.
Basel, September 01, 2021 — Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to add
Tonight! Novartis, Roche, BeiGene, Others Discuss Global Fight Against Cancer In Covid Era
11:46am, Friday, 27'th Aug 2021
Against that backdrop, Forbes China will hold the second “Forbes China Healthcare Summit” at 8pm ET tonight (8am on August 28 in China).
Lonza appoints Novartis executive as new Chief Financial Officer
01:24am, Thursday, 26'th Aug 2021
Lonza has appointed former Novartis executive Philippe Deecke as its new Chief Financial Officer, the Swiss chemicals company said on Thursday.
Novartis' STAMP Inhibitor Under FDA Review For Myeloid Leukemia
07:27am, Wednesday, 25'th Aug 2021
The FDA has accepted for review Novartis AG's (NYSE: NVS) marketing application seeking approval for asciminib (ABL001) in chronic myeloid leukemia (CML). Under Priority Review, the application is
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
01:15am, Tuesday, 24'th Aug 2021
Basel, August 24, 2021 — Novartis today announced an update on the Phase III BELINDA study investigating Kymriah® (tisagenlecleucel) in aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or
FDA, MSK, Novartis, Kevin Rudd To Discuss Int'l Collaboration To Fight Cancer On Aug. 27
12:36pm, Monday, 23'rd Aug 2021
Free event will be held online
Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies
06:17am, Tuesday, 17'th Aug 2021
Novartis AG (NYSE: NVS) has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept) 2 mg in patients wit
3 Reasons Novartis May Be Your Ticket To A Rich Retirement
11:53pm, Tuesday, 10'th Aug 2021
3 Reasons Novartis May Be Your Ticket To A Rich Retirement
Here Are the Winners of Cowen's Big Pharma R&D Showdown
10:02am, Saturday, 07'th Aug 2021
The Wall Street firm put big drugmakers' R&D programs through five different tests.
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
12:13pm, Wednesday, 04'th Aug 2021
Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer
02:03pm, Tuesday, 27'th Jul 2021
The FDA has granted Orphan Drug Designation to Novartis AG's (NYSE: NVS) NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer. NIS793 is a fully human anti-TGF-β Ig
Novartis Leading in $10 Billion Market for New Cancer Treatment
03:51pm, Monday, 26'th Jul 2021
Novartis AG ( NVS , Financial) is ahead of the pack of pharma companies developing a new type of cancer treatment that could evolve into a $10 billion market, reported the California News Times.
Novartis CEO says Covid-related doctor visit delays likely impacting cancer diagnosis rates
06:54pm, Wednesday, 21'st Jul 2021
Novartis CEO Vasant Narasimhan told CNBC there are now lower rates of diagnoses due to reduced hospital visits during the coronavirus pandemic.
